Possible Biomarkers To Predict Response In Patients With Myelodysplastic Syndromes (MDS) Or Acute Myeloid Leukemia (AML) Treated With 5-Azacitidine

被引：0
|
作者：
Kuendgen, Andrea
Mueller-Thomas, Catharina
Urbaniak, Petra
Lauseker, Michael
Haferlach, Torsten
Alpermann, Tamara
Albuquerque, Andreia
Kohlmann, Alexander
Schnittger, Susanne
Hildebrandt, Barbara
Royer-Pokora, Brigitte
Gattermann, Norbert
Haas, Rainer
Germing, Ulrich
Goetze, Katharina
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.2757.2757
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2757
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Distinct Genomic Associations to Predict Acute Myeloid Leukemia (AML) Progression from Myelodysplastic Syndromes (MDS)
    Madanat, Yazan F.
    Sekeres, Mikkael A.
    Mukherjee, Sudipto
    Al-Issa, Karam
    Hirsch, Cassandra M.
    Gerds, Aaron T.
    Jha, Babal K.
    Adema, Vera
    Advani, Anjali
    Nagata, Yasunobu
    Kuzmanovic, Teodora
    Carraway, Hetty E.
    Przychodzen, Bartlomiej
    Maciejewski, Jaroslaw P.
    Nazha, Aziz
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S261 - S261
  • [22] The Tolerability of Combination Therapy with Thalidomide and 5-Azacitidine in Patients with Advanced Myelodysplastic Syndromes (MDS).
    Kenealy, Melita K.
    Seymour, John F.
    Linda, Cowan
    Milner, Alvin
    Giri, Pratyush
    Ho, Shir-Jing
    Benson, Warwick
    Nicol, Andrew
    Campbell, Philip
    Prosser, Ian
    Underhill, Craig
    Cunningham, Ilona
    Mills, Anthony K.
    Szer, Jeffrey
    Presgrave, Peter
    Filshie, Robin
    BLOOD, 2009, 114 (22) : 695 - 695
  • [23] Population pharmacokinetic modelling of decitabine in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Mistry, B.
    Gibiansky, L.
    Hussein, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROMES (MDS): EFFECTS IN TREATMENT NAIVE AND RELAPSED/REFRACTORY PATIENTS
    Navada, S.
    Garcia-Manero, G.
    Hearn, K.
    Odchimar-Reissig, R.
    Demakos, E.
    Fenaux, P.
    Petrone, M.
    Zbyszewski, P.
    Fruchtman, S.
    Silverman, L.
    HAEMATOLOGICA, 2017, 102 : 183 - 184
  • [25] A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
    DiNardo, Courtney D.
    Olin, Rebecca
    Ishizawa, Jo
    Sumi, Hiroyuki
    Xie, Jingdong
    Kato, Kazunobu
    Kumar, Prasanna
    Andreeff, Michael
    BLOOD, 2019, 134
  • [26] Response rates in patients with acute myeloid leukemia (AML), treated with azacitidine, using WHO and international working group (IWG) criteria for myelodysplastic syndrome (MDS).
    Silverman, LR
    McKenzie, DR
    Peterson, BL
    Stone, RM
    Powell, BL
    Mayo, C
    Backstrom, JT
    Larson, RA
    BLOOD, 2005, 106 (11) : 525A - 526A
  • [27] Early response to therapy with 5-azacitidine and venetoclax in three transplant-ineligible patients with acute myeloid leukemia (AML)
    Steiner, L.
    Jawhar, M.
    Fabarius, A.
    Nowak, D.
    Hofmann, W. - K.
    Metzgeroth, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 203 - 203
  • [28] Outcome of Patients (pts) Treated for Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (s AML) After Azacitidine (AZA) Failure
    Prebet, Thomas
    Gore, Steven D.
    Esterni, Benjamin
    Itzykson, Raphael
    Thepot, Sylvain
    Beach, C. L.
    Fenaux, Pierre
    Vey, Norbert
    BLOOD, 2010, 116 (21) : 199 - 199
  • [29] EXTENDED CC-486 (ORAL AZACITIDINE) DOSING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), ACUTE MYELOID LEUKEMIA (AML), OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): SAFETY, TOLERABILITY, AND RESPONSE
    Savona, M. R.
    Kolibaba, K.
    Conkling, P.
    Kingsley, E. C.
    Becerra, C.
    Morris, J. C.
    Rifkin, R. M.
    Laille, E.
    Kellerman, A.
    Ukrainskyj, S. M.
    Dong, Q.
    Skikne, B. S.
    LEUKEMIA RESEARCH, 2015, 39 : S29 - S30
  • [30] Treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) in the elderly with azacitidine and gemtuzumab ozogamicin (GO)
    Nand, S.
    Godwin, J.
    Smith, S.
    Barton, K.
    Germano, E.
    Stiff, P.
    LEUKEMIA RESEARCH, 2007, 31 : S8 - S8
12345